Qiagen downgraded by Morgan Stanley with a new price target
$QGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Morgan Stanley downgraded Qiagen from Overweight to Equal-Weight and set a new price target of $48.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/4/2025 | Buy → Neutral | Redburn Atlantic | |
| 2/19/2025 | $52.00 → $42.00 | Outperform → Neutral | Robert W. Baird |
| 1/6/2025 | $48.00 | Overweight → Equal-Weight | Morgan Stanley |
| 12/10/2024 | $42.50 → $54.00 | Hold → Buy | Jefferies |
| 10/17/2024 | $49.00 | Buy → Hold | HSBC Securities |
| 6/27/2024 | $50.00 | Peer Perform → Outperform | Wolfe Research |
| 12/19/2023 | $44.00 | Equal Weight | Wells Fargo |
| 12/13/2023 | Peer Perform | Wolfe Research |
SD - QIAGEN N.V. (0001015820) (Filer)
SCHEDULE 13G/A - QIAGEN N.V. (0001015820) (Subject)
6-K - QIAGEN N.V. (0001015820) (Filer)
Redburn Atlantic downgraded Qiagen from Buy to Neutral
Robert W. Baird downgraded Qiagen from Outperform to Neutral and set a new price target of $42.00 from $52.00 previously
Morgan Stanley downgraded Qiagen from Overweight to Equal-Weight and set a new price target of $48.00
GENCURIX partnership marks launch of new QIAcuityDx Partnering Program for third-party in vitro diagnostic (IVD) assay development GENCURIX signs as inaugural partner to develop multiplex oncology assays for tissue and liquid biopsies Partnership aims to broaden adoption of QIAcuityDx Four platform offering clinical diagnostic laboratories a range of clinical oncology assays QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a high-performance digital PCR system designed for clinical diagnostics. GENCURIX is the first development partner under QI
QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies Companion diagnostic to identify key disease-causing mutations in patients with MPNs, with an initial focus on mutant CALR the second most common driver of MPNs Panel to be validated on Illumina NextSeq 550Dx platform for use with whole blood samples Partnership supports Incyte's extensive portfolio in myeloproliferative neoplasms, including INCA033989, and enhances QIAGEN's onco-hematology diagnostics pipeline QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) and Incyte (NASDAQ:INCY) today announced a ne
Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) to co-develop and commercialize minimal residual disease (MRD) assays for solid tumors on QIAGEN's QIAcuity digital PCR platform. This collaboration aims to deliver highly sensitive, cost-effective, and decentralized MRD testing solutions that enable oncologists to monitor cancer recurrence and guide personalized treatment decisions using minimally invasive blood samples. "Partnering with QIAGEN enables Tracer to bring our solid tumor MRD expertise to a broader market using a robust digital PCR platform i
LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its
BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ -- Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology industry. As CDO, Chan will play a key leadership role in advancing Actym's pipeline of first-in-class, systemically administered therapeutics that re-program the immunosuppressive microenvironment in solid tumors. Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer."Chan has significant experience advancing novel cancer
JERSEY, Channel Islands, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mohammad El Khoury as the Company's Chief Commercial Officer. In this role, Mr. El Khoury will oversee all commercial activities for the company as it continues to expand globally. "I am delighted to welcome a strong and experienced commercial leader like Mohammad to the Executive team. During the last 30 years, he has been partnering with customers across the globe. Mohammad will be instrumental in accelerating the commercialization of our MosaiQ solution. He will continue to build the commercial team and expand the distribution channels whil
Q1 2025 results confirm preliminary announcement: Net sales of $483 million (+5% actual rates, +7% constant exchange rates, CER); adjusted diluted EPS of $0.55 Net sales growth of +7% CER ahead of outlook for about +3% CER growth and adjusted diluted EPS of $0.56 CER ahead of outlook for at least $0.50 CER 29.8% adj. operating income margin up 4.1 percentage points vs. 25.7% in Q1 2024 Operating cash flow of $140 million in Q1 2025 vs. $133 million in Q1 2024 Proposal at Annual General Meeting to introduce a dividend as expansion of capital allocation strategy, also seek authorization for a new $500 million share repurchase Stephen H. Rusckowski proposed to become new Chairman
QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board will propose the initiation of an annual cash dividend under an amended dividend policy to QIAGEN's shareholders at the next Annual General Meeting scheduled for June 26, 2025. This milestone reflects QIAGEN's strategy to introduce a new avenue to increase shareholder returns while preserving flexibility to reinvest in long-term growth. The Supervisory Board's decision on the amended dividend policy and initial dividend payment is subject to approval by QIAGEN's shareholders. The initial dividend payment would consist of $0.25 per ordinary share. This proposal represents a total payout of a
QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, May 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2480 Conference ID: 5803222 To avoid waiting time, please join the event conference 5-10 minute
SC 13G - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)